@khalenJG I asked a friend recently, “Do you think suffering is a rite of passage? That many people today struggle because they haven’t gone through that right of passage (too many modern comforts)?”
Cresilon announced today it has received FDA 510(k) clearance for TRAUMAGEL for temporary external use for controlling moderate to severe bleeding.
This is a major advancement for our company and the fields of emergency medicine and trauma care. Our second FDA clearance brings us much closer to achieving our mission – saving lives by transforming trauma care and setting a new standard in stopping bleeding.
“The ability to rapidly stop bleeding at the point of care and halt a life-threatening hemorrhage can be the difference between life and death for people with traumatic injuries,” said Joe Landolina, CEO and co-founder of Cresilon and inventor of the technology. “The FDA clearance for TRAUMAGEL is a monumental milestone for Cresilon and brings us another step forward in our mission to save lives and transform the standard of care in emergency medicine. Our proprietary hemostatic gel technology is a game-changer and unlike any other hemostatic agents currently being used.”
Stay tuned as we continue moving forward following TRAUMAGEL's FDA clearance.
Read more here: https://t.co/JT4EMdiWz8
#innovation #technology #lifescience #medtech